Journal article
Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines
British journal of cancer, Vol.81(8), pp.1304-1310
12/01/1999
DOI: 10.1038/sj.bjc.6694384
PMCID: PMC2362978
PMID: 10604726
Abstract
Recent data suggest that expression of the membrane P
170
-glycoprotein (P-gp) may confer resistance to the topoisomerase- I-interactive agent topotecan. The present study describes the cellular effects of a new dihydropyridine analogue, PAK-200S, on P-gp-mediated resistance to topotecan in human breast and ovarian tumour cells. PAK-200S at a non-cytotoxic concentration of 2.0 μ
M
completely reversed resistance to topotecan in P-gp-expressing MCF-7/adr (breast) and A2780/Dx5 (ovarian) tumour cells, respectively, with no effects on parental cells. Cellular pharmacokinetic studies by reversed-phase high-performance liquid chromatography analysis showed significantly lower cellular drug concentrations of the pharmacologically active closed-ring lactone of topotecan in multidrug-resistant cells than in parental cells. PAK-200S was effective in restoring the cellular lactone concentrations of topotecan in resistant MCF-7/adr cells to levels comparable to those obtained in parental cells. Furthermore, exposure of MCF-7/adr cells to topotecan in the presence of PAK-200S significantly increased the induction of protein-linked DNA breaks. PAK-200S did not alter nuclear topoisomerase I-mediated ex vivo pBR322 DNA plasmid unwinding activity and topoisomerase-I protein expression. These results suggest that reversal of P-gp-mediated resistance to topotecan by PAK-200S was related to the restoration of cellular drug concentrations of the active lactone form of topotecan rather than a direct effect on topoisomerase-I function. © 1999 Cancer Research Campaign
Details
- Title: Subtitle
- Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines
- Creators
- U Vanhoefer - German Cancer Research CenterM R Müller - Department of Internal Medicine (Cancer Research), West German Cancer Center, University of Essen Medical School, Essen, GermanyR A Hilger - Department of Internal Medicine (Cancer Research), West German Cancer Center, University of Essen Medical School, Essen, GermanyB Lindtner - Department of Internal Medicine (Cancer Research), West German Cancer Center, University of Essen Medical School, Essen, GermanyU Klaassen - Department of Internal Medicine (Cancer Research), West German Cancer Center, University of Essen Medical School, Essen, GermanyN Schleucher - Department of Internal Medicine (Cancer Research), West German Cancer Center, University of Essen Medical School, Essen, GermanyY M Rustum - Roswell Park Cancer InstituteS Seeber - Department of Internal Medicine (Cancer Research), West German Cancer Center, University of Essen Medical School, Essen, Germany
- Resource Type
- Journal article
- Publication Details
- British journal of cancer, Vol.81(8), pp.1304-1310
- DOI
- 10.1038/sj.bjc.6694384
- PMID
- 10604726
- PMCID
- PMC2362978
- NLM abbreviation
- Br J Cancer
- ISSN
- 0007-0920
- eISSN
- 1532-1827
- Publisher
- Nature Publishing Group
- Language
- English
- Date published
- 12/01/1999
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984360149802771
Metrics
12 Record Views